Peter Stock, MD
Surgery · San Francisco, CANPI 1801850805
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $26,185 of the $36,804 with a category attached, or 71.1%. Astellas Pharma Inc accounts for 65.7% of it on its own, with 2 other manufacturers making up the rest. Among surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 12 payments — averaging $3067.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Inc$24K
- Vertex$13K
- Veloxis Pharmaceuticals, Inc.$134
Across 4 payments — averaging $1,617,790 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$6.5M
What the payments were for
- Consulting fees$10,48528%
- Travel & lodging$26,18571%
- Food & beverage$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Inc | 4 | $24,166 |
| Vertex | 7 | $12,504 |
| Veloxis Pharmaceuticals, Inc. | 1 | $134 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACROLIMUS$24,166
- Envarsus$269
How this compares
$36,804 in reported general payments places this provider in the 90th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisone | 11 | $46 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $28 |
Paid to pharmacies, not to this prescriber.
Other surgery in San Francisco
- Timothy ChuterSan Francisco$8.8M
- Shane BurchSan Francisco$500K
- Charles EichlerSan Francisco$310K
- Michael AlvaradoSan Francisco$201K
- Scott HansenSan Francisco$186K
- Santiago HorganSan Diego$2.8M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.